EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting YAP/TAZ in Combination with PD-L1 Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC)

Kostas A Papavassiliou iD, Georgios Marinos, Athanasios G Papavassiliou iD

Cells · 10.03.2023 · 12 (6) · 871

DOI: 10.3390/cells12060871 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, online erschienen am 10.03.2023. Verfasst von Kostas A Papavassiliou und 2 weiteren Autor:innen. Beteiligte Einrichtung: First University Department of Respiratory Medicine, "Sotiria" Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The survival of non-small cell lung cancer (NSCLC) patients has improved in the last decade as a result of introducing new therapeutics, such as immune checkpoint inhibitors, in the clinic. Still, some NSCLC patients do not benefit from these therapies due to intrinsic resistance or the development of acquired resistance and their malignant disease progresses. Further research on the molecular underpinnings of NSCLC pathobiology is required in order to discover clinically relevant molecular targets that regulate tumor immunity and to develop reasonable therapeutic combinations that will promote the efficacy of immune checkpoint inhibitors. Yes-associated Protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ), the final effectors of the Hippo signaling transduction pathway, are emerging as key players in NSCLC development and progression. Herein, we overview studies that have investigated the oncogenic role of YAP/TAZ in NSCLC, focusing on immune evasion, and highlight the therapeutic potential of combining YAP/TAZ inhibitory agents with immune checkpoint inhibitors for the management of NSCLC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansImmune Checkpoint InhibitorsSignal TransductionB7-H1 Antigen

Stichwörter der Autor:innen

Yes-associated Protein (YAP)immune checkpoint inhibitorsnon-small cell lung cancer (NSCLC)programmed cell death protein-1 (PD-1)programmed cell death-ligand 1 (PD-L1)transcriptional coactivator with PDZ-binding motif (TAZ)

Substanzen

Immune Checkpoint InhibitorsB7-H1 Antigen

Autor:innen und Institutionen

  • First University Department of Respiratory Medicine, "Sotiria" Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
  • Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
  • Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.

ORCID-Profile: Kostas A Papavassiliou, Athanasios G Papavassiliou

Zitieren

APA

Papavassiliou, K. A., Marinos, G., & Papavassiliou, A. G. (2023). Targeting YAP/TAZ in Combination with PD-L1 Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC). Cells, 12(6), 871. https://doi.org/10.3390/cells12060871

Vancouver

Papavassiliou KA, Marinos G, Papavassiliou AG. Targeting YAP/TAZ in Combination with PD-L1 Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC). Cells. 2023;12(6):871. doi:10.3390/cells12060871

BibTeX
@article{Papavassiliou2023,
  author = {Papavassiliou, Kostas A and Marinos, Georgios and Papavassiliou, Athanasios G},
  title = {Targeting YAP/TAZ in Combination with PD-L1 Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC)},
  journal = {Cells},
  year = {2023},
  volume = {12},
  number = {6},
  pages = {871},
  doi = {10.3390/cells12060871}
}
Kostenlos starten →